<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transfusion</journal-id><journal-id journal-id-type="iso-abbrev">Transfusion</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1537-2995</journal-id><journal-id journal-id-type="publisher-id">TRF</journal-id><journal-title-group><journal-title>Transfusion</journal-title></journal-title-group><issn pub-type="ppub">0041-1132</issn><issn pub-type="epub">1537-2995</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Hoboken, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7461313</article-id><article-id pub-id-type="doi">10.1111/trf.16015</article-id><article-id pub-id-type="publisher-id">TRF16015</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Persistence of <styled-content style="fixed-case" toggle="no">SARS&#x02010;CoV</styled-content>&#x02010;2 nasopharyngeal swab <styled-content style="fixed-case" toggle="no">PCR</styled-content> positivity in <styled-content style="fixed-case" toggle="no">COVID</styled-content>&#x02010;19 convalescent plasma donors</article-title><alt-title alt-title-type="left-running-head">Ikegami et al.</alt-title></title-group><contrib-group><contrib id="trf16015-cr-0001" contrib-type="author"><name><surname>Ikegami</surname><given-names>Sachie</given-names></name><xref ref-type="aff" rid="trf16015-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="trf16015-cr-0002" contrib-type="author"><name><surname>Benirschke</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="trf16015-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="trf16015-cr-0003" contrib-type="author"><name><surname>Flanagan</surname><given-names>Tara</given-names></name><xref ref-type="aff" rid="trf16015-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="trf16015-cr-0004" contrib-type="author"><name><surname>Tanna</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="trf16015-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="trf16015-cr-0005" contrib-type="author"><name><surname>Klein</surname><given-names>Tovah</given-names></name><xref ref-type="aff" rid="trf16015-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="trf16015-cr-0006" contrib-type="author"><name><surname>Elue</surname><given-names>Rita</given-names></name><xref ref-type="aff" rid="trf16015-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="trf16015-cr-0007" contrib-type="author"><name><surname>Debosz</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="trf16015-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="trf16015-cr-0008" contrib-type="author"><name><surname>Mallek</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="trf16015-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="trf16015-cr-0009" contrib-type="author"><name><surname>Wright</surname><given-names>Gregory</given-names></name><xref ref-type="aff" rid="trf16015-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="trf16015-cr-0010" contrib-type="author"><name><surname>Guariglia</surname><given-names>Perry</given-names></name><xref ref-type="aff" rid="trf16015-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="trf16015-cr-0011" contrib-type="author"><name><surname>Kang</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="trf16015-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="trf16015-cr-0012" contrib-type="author" corresp="yes"><name><surname>Gniadek</surname><given-names>Thomas J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4092-9397</contrib-id><xref ref-type="aff" rid="trf16015-aff-0001">
<sup>1</sup>
</xref><address><email>thomas.gniadek@gmail.com</email></address></contrib></contrib-group><aff id="trf16015-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Pathology and Laboratory Medicine</named-content>
<institution>NorthShore University HealthSystem</institution>
<city>Evanston</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><aff id="trf16015-aff-0002">
<label><sup>2</sup></label>
<institution>NorthShore University HealthSystem</institution>
<city>Evanston</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><aff id="trf16015-aff-0003">
<label><sup>3</sup></label>
<institution>NorthShore University Health System, Swedish Hospital</institution>
<city>Chicago</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Thomas J. Gniadek, Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, 2650 Ridge Ave, Evanston, IL 60201.<break/>
Email: <email>thomas.gniadek@gmail.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>8</month><year>2020</year></pub-date><elocation-id>10.1111/trf.16015</elocation-id><history><date date-type="received"><day>17</day><month>5</month><year>2020</year></date><date date-type="rev-recd"><day>21</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 AABB <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 AABB</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:TRF-9999-na.pdf"/><abstract><title>Abstract</title><sec id="trf16015-sec-0001"><title>Background</title><p>Nucleic acid persists after symptom resolution and infectivity for many viral infections via delayed clearance of nucleic acid fragments, non&#x02010;infectious particles, or transmissible virus. For Coronavirus Disease 2019 (COVID&#x02010;19), the relationship between nasopharyngeal (NP) swab positivity, the development of antibodies against COVID&#x02010;19, and clinical history are unclear.</p></sec><sec id="trf16015-sec-0002"><title>Study design and methods</title><p>Individuals who recovered from COVID&#x02010;19 and volunteered to donate convalescent plasma (CP) were screened by NP swab PCR, responded to a questionnaire, and were tested for anti&#x02010;COVID&#x02010;19 antibodies.</p></sec><sec id="trf16015-sec-0003"><title>Results</title><p>A proportion of 11.8% of individuals tested positive for SARS&#x02010;CoV&#x02010;2 by NP swab PCR greater than 14&#x02009;days after the resolution of symptoms of active disease, including one donor who had asymptomatic disease and tested positive by NP swab 41&#x02009;days after her initial diagnosis. Clinical history did not show a significant correlation with persistence of NP swab positivity. Also, NP swab positivity &#x0003e;14&#x02009;days from symptom resolution did not correlate with anti&#x02010;COVID&#x02010;19 serology results. IgG anti&#x02010;SARS&#x02010;CoV&#x02010;2 spike antibody strength correlated with hospitalization for COVID&#x02010;19 using two different assays. Total anti&#x02010;SARS&#x02010;CoV&#x02010;2 nucleocapsid antibody strength correlated with time from symptom resolution to sample collection and symptom duration.</p></sec><sec id="trf16015-sec-0004"><title>Conclusions</title><p>SARS&#x02010;CoV&#x02010;2 nucleic acid is detectable long after the resolution of symptoms in a significant percentage of previously diagnosed individuals, which is important to consider when interpreting PCR swab results. Persistence of PCR positivity does not correlate with antibody strength or symptoms of COVID&#x02010;19. If anti&#x02010;spike antibody is used to assess CP potency, individuals who suffered severe COVID&#x02010;19 disease symptoms may represent better donors.</p></sec></abstract><funding-group><award-group id="funding-0001"><funding-source>Private donations to the NorthShore Foundation, including a donation from The Rice Foundation</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="7"/><word-count count="3740"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.8 mode:remove_FC converted:01.09.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="trf16015-cit-9001">
<string-name>
<surname>Ikegami</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Benirschke</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Flanagan</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Persistence of <styled-content style="fixed-case" toggle="no">SARS&#x02010;CoV</styled-content>&#x02010;2 nasopharyngeal swab <styled-content style="fixed-case" toggle="no">PCR</styled-content> positivity in <styled-content style="fixed-case" toggle="no">COVID</styled-content>&#x02010;19 convalescent plasma donors</article-title>. <source xml:lang="en">Transfusion</source>. <year>2020</year>;<fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/trf.16015</pub-id>
<pub-id pub-id-type="pmid">31898351</pub-id></mixed-citation>
</p><fn-group><fn id="trf16015-note-1002"><p>
<bold>Funding information</bold> Private donations to the NorthShore Foundation, including a donation from The Rice Foundation</p></fn></fn-group></notes></front><body id="trf16015-body-0001"><sec id="trf16015-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Coronavirus Disease 2019 (COVID&#x02010;19) convalescent plasma (CP) was widely proposed as a potential therapy for COVID&#x02010;19 in the United States (US) during the initial months of viral spread within the country.<xref rid="trf16015-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="trf16015-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> Prior to that, it was used to treat a limited number of COVID&#x02010;19 patients in China, with suggestion of possible efficacy and no clear adverse effects.<xref rid="trf16015-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> Furthermore, CP has been utilized during epidemics for nearly 100&#x02009;years.<xref rid="trf16015-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> A number of hospital&#x02010;based and national blood collection centers, including the NorthShore University HealthSystem Blood Bank, rapidly began convalescent plasma collection programs as an Institutional Review Board (IRB) approved clinical research program.</p><p>The use of convalescent plasma in the US was enabled by the US Food and Drug Administration (FDA) and the FDA recommendations for the collection of convalescent plasma changed quickly during the spring of 2020.<xref rid="trf16015-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> Initially, the FDA stated that donors between 14 and 28&#x02009;days of symptom resolution should test negative for SARS&#x02010;CoV&#x02010;2 PCR by testing either a nasopharyngeal (NP) swab or the blood product of the itself. Due to a lack of validated blood product PCR assays, most institutions either utilized NP swab or waited until after 28&#x02009;days from symptom resolution before collecting plasma. Interestingly, many potential donors who were tested by NP swab remained positive &#x0003e;14&#x02009;days from resolution of symptoms. Subsequently, the FDA changed their guidance to state that a confirmatory negative test was not necessary, even for donors who presented as early as 14&#x02009;days after symptom resolution.</p><p>Similarly, the Center for Disease Control (CDC) established a &#x0201c;no&#x02010;test&#x0201d; criteria to allow healthcare workers to return to work without confirmatory testing to ensure they are negative for COVID&#x02010;19 by PCR.<xref rid="trf16015-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> Since contact tracing in most states within the US remains underutilized, the possibility of low&#x02010;level infectivity weeks after symptom resolution has not been completely excluded. Therefore, the significance of persistently positive SARS&#x02010;CoV&#x02010;2 NP swab remains unclear. Perhaps reassuringly, other viral infections are known to cause positive PCR tests, even after infectivity has ended.<xref rid="trf16015-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> Conversely, there are reports of coronaviruses causing persistent asymptomatic infections in cats, with live and transmissible virus in some individuals.<xref rid="trf16015-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> Additionally, asymptomatic respiratory coronavirus infections in humans are widespread and of unclear persistence.<xref rid="trf16015-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>
</p><p>Due in part to early reports of potential asymptomatic transmission, the NorthShore CP collection study began testing all potential donors by NP swab PCR.<xref rid="trf16015-bib-0010" ref-type="ref">
<sup>10</sup>
</xref> This approach permitted investigation into the factors associated with persistent NP swab PCR positivity for SARS&#x02010;CoV&#x02010;2. In particular, we investigated whether donor characteristics or COVID&#x02010;19 symptom history were associated with the duration of NP swab PCR positivity. Furthermore, we investigated whether serology test results correlated with clinical history or the persistence of NP swab PCR positivity.</p></sec><sec id="trf16015-sec-0006"><label>2</label><title>MATERIALS AND METHODS</title><sec id="trf16015-sec-0007"><label>2.1</label><title>Donor recruitment</title><p>All participants contacted the NorthShore University HealthSystem Blood Bank to enroll in the IRB approved convalescent plasma collection study. The collection program was listed on a national website for COVID&#x02010;19 CP (<ext-link ext-link-type="uri" xlink:href="http://www.ccpp19.org">www.ccpp19.org</ext-link>) and physicians within the NorthShore University HealthSystem were notified of the collection program by professional staff memo, with instructions on how to direct patients to the blood bank.</p><p>Potential participants were screened and scheduled by phone to ensure a history of a positive SARS&#x02010;CoV&#x02010;2 test result (PCR or serology) and&#x02009;&#x0003e;14&#x02009;days from complete resolution of symptoms of active disease, which included (at least) extreme fatigue, cough, sore throat, fever, and diarrhea. Persistent loss of taste and/or smell was not considered a symptom of active disease. Phone screening involved notification that CP donors must also satisfy routine blood donor screening criteria, however a detailed donor history screening was not done by phone.</p><p>When donors presented for consent, they were asked to fill out a form that included a free&#x02010;text report of COVID&#x02010;19 symptoms and demographic information. Free text results were grouped into numerical variables of age, symptom duration, days from symptom resolution to sample collection, and maximum temperature (if febrile and measured). The categorical variables of initial NP swab result and sex were analyzed, along with variables related to COVID&#x02010;19 disease symptoms: fever, loss of taste/smell, diarrhea, chills, aches, fatigue, night sweats, headaches, cough, sore throat, shortness of breath, chest tightness, other respiratory symptoms, gastrointestinal symptoms, skin symptoms (rash or hives), hospitalization, receiving treatment, history of autoimmune disease, history of past drug reactions, and history of bleeding or clotting disorder. Symptoms not reported in the free text fields were assumed to be negative/normal.</p></sec><sec id="trf16015-sec-0008"><label>2.2</label><title>Nasopharyngeal swab <styled-content style="fixed-case" toggle="no">PCR</styled-content>
</title><p>Participants were screened by rapid NP PCR approved under a US Food and Drug Administration Emergency Use Authorization (ID NOW, Abbott Laboratories, Chicago, IL). Swabs were tested immediately after sampling, without being placed in viral transport media. Individuals who tested positive by NP PCR were offered to be re&#x02010;tested if they returned in 1&#x02010;2&#x02009;weeks.</p></sec><sec id="trf16015-sec-0009"><label>2.3</label><title>Serology testing</title><p>A subset of the total enrolled population had samples drawn for serology testing and sufficient volume available for serology testing using three in&#x02010;house assays. These samples were collected from 214 donors. Anti&#x02010;SARS&#x02010;CoV&#x02010;2 spike protein antibody testing was performed using the LIAISON SARS&#x02010;CoV&#x02010;2 S1/S2 IgG (DiaSorin Inc, Saluggia, Italy) as well as the Access SARS&#x02010;COVID&#x02010;2 IgG assay (Beckman Coulter, Brea, CA). Anti&#x02010;SARS&#x02010;CoV&#x02010;2 nucleocapsid protein antibody testing was performed using the Elecsys Anti&#x02010;SARS&#x02010;CoV&#x02010;2 (Roche Diagnostics, Basal, Switzerland). Importantly, the Roche assay tests for total (not isotype specific) anti&#x02010;SARS&#x02010;CoV&#x02010;2 nucleocapsid reactivity. The quantitative cut&#x02010;off index for each assay was used to assess antibody strength.</p></sec><sec id="trf16015-sec-0010"><label>2.4</label><title>Statistical analysis</title><p>To test for correlations between clinical history and persistence of NP swab PCR positivity, a per&#x02010;swab analysis was performed by grouping swab results based on the number of days post symptom resolution when it was collected. Donors were not swabbed more often than once per week. All swabs taken greater or equal to 50&#x02009;days from symptom resolution were grouped; one donor had two swabs within this group and the latter was used for analysis. Otherwise, all donors had only one swab per time period considered.</p><p>Unpaired student t&#x02010;test with unequal variance was performed using Microsoft Excel (Microscoft Corporation, Redmond, WA) to evaluate the statistical differences in numerical variables. Univariate analysis for associations between categorical variables were assessed using Fisher's exact test on a 2&#x02010;by&#x02010;2 contingency table in R (R Foundation for Statistical Computing, Vienna, Austria) using stats package v4, with a null hypothesis that the odds ratio is equal to 1 and alternative hypothesis that the odds ratio is not equal to 1. The Bonferroni correction was used to assess the statistical significance of p&#x02010;values, therefore (given 20 tests performed, see Table <xref rid="trf16015-tbl-0001" ref-type="table">1</xref>) a p&#x02010;value of less than or equal to 0.0025 was considered significant for the univariate analyses.<xref rid="trf16015-bib-0011" ref-type="ref">
<sup>11</sup>
</xref>
</p><table-wrap id="trf16015-tbl-0001" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Demographics and clinical characteristics of convalescent plasma donors</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Total donors, N</th><th align="left" valign="bottom" rowspan="1" colspan="1">272</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, median (range) y</td><td align="char" valign="top" rowspan="1" colspan="1">44.9 (19&#x02010;77)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="char" valign="top" rowspan="1" colspan="1">130 (47.8%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="char" valign="top" rowspan="1" colspan="1">142 (52.2%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COVID&#x02010;19 symptoms</td><td align="char" valign="top" rowspan="1" colspan="1">266 (97.8%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cough</td><td align="char" valign="top" rowspan="1" colspan="1">139 (51.1%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fatigue</td><td align="char" valign="top" rowspan="1" colspan="1">138 (50.7%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Muscle/body aches</td><td align="char" valign="top" rowspan="1" colspan="1">132 (48.5%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Loss of taste/smell</td><td align="char" valign="top" rowspan="1" colspan="1">124 (45.6%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fever (temperature&#x02009;&#x0003e;&#x02009;100.4 F)</td><td align="char" valign="top" rowspan="1" colspan="1">111 (40.8%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Headache</td><td align="char" valign="top" rowspan="1" colspan="1">91 (33.4%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sore throat</td><td align="char" valign="top" rowspan="1" colspan="1">63 (23.2%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Chills</td><td align="char" valign="top" rowspan="1" colspan="1">59 (21.7%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Shortness of breath</td><td align="char" valign="top" rowspan="1" colspan="1">56 (20.6%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td><td align="char" valign="top" rowspan="1" colspan="1">52 (19.1%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other gastrointestinal symptoms</td><td align="char" valign="top" rowspan="1" colspan="1">38 (14.0%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Chest tightness</td><td align="char" valign="top" rowspan="1" colspan="1">36 (13.2%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Night sweats</td><td align="char" valign="top" rowspan="1" colspan="1">21 (7.7%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Skin rash or hives</td><td align="char" valign="top" rowspan="1" colspan="1">12 (4.4%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of hospitalization for COVID&#x02010;19</td><td align="char" valign="top" rowspan="1" colspan="1">10 (3.79%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of treatment for COVID&#x02010;19</td><td align="char" valign="top" rowspan="1" colspan="1">27 (9.9%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Azithromycin</td><td align="char" valign="top" rowspan="1" colspan="1">9 (3.3%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hydroxychloroquine</td><td align="char" valign="top" rowspan="1" colspan="1">7 (2.6%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Tylenol</td><td align="char" valign="top" rowspan="1" colspan="1">5 (1.8%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Convalescent plasma</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="char" valign="top" rowspan="1" colspan="1">10 (3.7%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of drug reaction</td><td align="char" valign="top" rowspan="1" colspan="1">25 (9.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of autoimmune disease</td><td align="char" valign="top" rowspan="1" colspan="1">9 (3.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of bleeding or clotting</td><td align="char" valign="top" rowspan="1" colspan="1">4 (1.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of use of convalescent plasma, N (%)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0%)</td></tr></tbody></table><table-wrap-foot id="trf16015-ntgp-0002"><fn id="trf16015-note-0002"><p>
<italic>Note:</italic> Symptoms are those experienced during COVID&#x02010;19 disease. Other treatment included cough medicine, other antibiotics, and inhalers.</p></fn></table-wrap-foot></table-wrap><p>The relationship between serology results and NP swab positivity/clinical history was assessed using multivariate linear regression in R. In addition to the COVID&#x02010;19 symptoms listed in Table <xref rid="trf16015-tbl-0001" ref-type="table">1</xref>, the model considered whether the individual was febrile (temperature&#x02009;&#x0003e;&#x02009;100.4 F), sex, days post symptom resolution to serology test collection, initial NP swab result, age, and symptom duration. To avoid oversampling donors who were tested by NP swab more than once, only the first NP swab result for each donor was considered.</p></sec></sec><sec id="trf16015-sec-0011"><label>3</label><title>RESULTS</title><sec id="trf16015-sec-0012"><label>3.1</label><title>Donor characteristics</title><p>Between April 14, 2020 and June 9, 2020, a total of 272 donors enrolled the NorthShore University Health System convalescent plasma collection study. Median donor age was 47.8&#x02009;years (range 19 to 77); 130 (47.8%) of the donors were male and 142 (52.2%) were female. The median time from symptom resolution to the initial NP swab test was 36.3&#x02009;days (maximum 79&#x02009;days), see Table <xref rid="trf16015-tbl-0001" ref-type="table">1</xref>.</p></sec><sec id="trf16015-sec-0013"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">COVID</styled-content>&#x02010;19 history</title><p>The median duration of COVID&#x02010;19 symptoms was 13.6&#x02009;days (range 0 to 65). Ten donors (3.7%) were hospitalized for COVID&#x02010;19, and none of them received a convalescent plasma for the therapy. Self&#x02010;reported clinical symptoms of COVID&#x02010;19 are shown in Table <xref rid="trf16015-tbl-0001" ref-type="table">1</xref>. Most of the donors described these symptoms as mild to non&#x02010;severe. Six (2.2%) donors reported no symptoms of COVID&#x02010;19.</p></sec><sec id="trf16015-sec-0014"><label>3.3</label><title>Persistence of <styled-content style="fixed-case" toggle="no">NP</styled-content> swab <styled-content style="fixed-case" toggle="no">PCR</styled-content> positivity</title><p>Initial NP Swab PCR was positive in 32 (11.8%) potential donors. The median time from symptom resolution to the initial positive swab was 31.8 &#x000b1;&#x02009;14.8&#x02009;days. Donors who tested positive were offered serial follow&#x02010;up with repeat NP swab in 7&#x02010;14&#x02009;days. By June 29, 2020 a total of 300 NP swabs were performed on these 272 donors. Six donors were positive initially and positive when they returned for a second swab; of those, four were negative when tested a third time. One donor remained positive by NP swab 75&#x02009;days after the resolution of symptoms, after three consecutive positive swabs. Ten donors who tested positive initially did not return for a subsequent swab, while one donor positive on their second swab did not return for a third.</p><p>Analyzing NP swabs performed in the time periods of &#x02264;21, 22&#x02010;28, 29&#x02010;35, 36&#x02010;42, 43&#x02010;49, &#x02265;50&#x02009;days after the resolution of symptoms, the positivity rate was 12.2%, 20.9%, 14.3%, 9.1%, 16.3%, and 5.8%, respectively (see Figure <xref rid="trf16015-fig-0001" ref-type="fig">1A</xref>). One individual who did not have any symptoms of COVID&#x02010;19 had a positive swab (41&#x02009;days after diagnosis of COVID&#x02010;19 by PCR).</p><fig fig-type="FIGURE" xml:lang="en" id="trf16015-fig-0001" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>Nasopharyngeal (NP) swab positivity after symptom resolution. Percent positive NP swabs during each week&#x02010;long period post symptom resolution is shown for the donor population overall (A) and broken down into donor age groups (B)</p></caption><graphic id="nlm-graphic-1" xlink:href="TRF-9999-na-g001"/></fig><p>Donor characteristics and COVID&#x02010;19 symptom history (see Table <xref rid="trf16015-tbl-0001" ref-type="table">1</xref>) were compared between positive NP swabs and negative NP swabs within one&#x02010;week time periods from symptom resolution to swab collection. There was no correlation between donor age and persistence of PCR positivity (Figure <xref rid="trf16015-fig-0001" ref-type="fig">1B</xref>). There was a slight correlation between loss of taste/smell and the persistence of NP swab positivity. On the other hand, there was a possible inverse relationship between the symptom of diarrhea and persistence of NP swab positivity (Figure <xref rid="trf16015-fig-0002" ref-type="fig">2</xref>). However, these correlations did not reach statistical significance after correcting for multiple observations.</p><fig fig-type="FIGURE" xml:lang="en" id="trf16015-fig-0002" orientation="portrait" position="float"><label>FIGURE 2</label><caption><p>Diarrhea and Loss of Taste/Smell. Neither the presence nor absence of diarrhea or loss of taste/smell showed a statistically significant association with the positive NP swab rate during each time period (&#x02264;21, 22&#x02010;28, 29&#x02010;35, 26&#x02010;42, 43&#x02010;49, and&#x02009;&#x02265;50&#x02009;days post symptom resolution). For loss of taste/smell, <italic>P</italic> values were .28 and .14 during the 22&#x02010;28 and 29&#x02010;35&#x02009;day time periods, respectively (Fisher exact test)</p></caption><graphic id="nlm-graphic-3" xlink:href="TRF-9999-na-g002"/></fig><p>Multivariate analysis of the serology test results revealed no significant correlation between antibody cut&#x02010;off index and whether a donor had a positive NP swab. The anti&#x02010;nucleocapsid total antibody cut&#x02010;off index was significantly higher for samples collected a greater number of days from symptom resolution (<italic>P</italic> =&#x02009;.00007) and samples from donors who had a longer symptom duration (<italic>P</italic> =&#x02009;.001). The Beckman anti&#x02010;spike cutoff index was significantly higher for donors who had been hospitalized (0.00002), received treatment for COVID&#x02010;19 (<italic>P</italic> =&#x02009;.01), and were older (<italic>P</italic> =&#x02009;.02). Similarly, the DiaSorin anti&#x02010;spike cutoff index was higher for donors who had been hospitalized (<italic>P</italic> =&#x02009;.007), See Figure <xref rid="trf16015-fig-0003" ref-type="fig">3</xref>. For patients who were hospitalized for COVID&#x02010;19, median anti&#x02010;spike cutoff index was 32.0 &#x000b1;&#x02009;15.4 (Beckman) and 151.9 &#x000b1;&#x02009;73.7 (DiaSorin) verses 8.3 &#x000b1;&#x02009;9.8 and 64.3 &#x000b1;&#x02009;55.7 for non&#x02010;hospitalized patients, respectively. The other factors tested did not show a statistically significant effect on serology results.</p><fig fig-type="FIGURE" xml:lang="en" id="trf16015-fig-0003" orientation="portrait" position="float"><label>FIGURE 3</label><caption><p>Correlation between serology results and donor factors. Cutoff indices are shown for Beckman SARS&#x02010;CoV&#x02010;2 IgG Antibody Assay (white), Roche SARS&#x02010;CoV&#x02010;2 Total Antibody Assay (light gray), and Diasorin SARS&#x02010;CoV&#x02010;2 IgG Antibody Assay (dark gray) relative to select patient characteristics. With the IgG assays, patients hospitalized or who received treatment had a statistically significant increase in cutoff index values, which was not seen with the total antibody assay (A and B). Increasing age was positively correlated with increasing cutoff indices for the Beckman IgG assay (C). Increasing symptom duration was found to be positively associated with increasing cutoff indices measured in the total antibody assay, but not for the IgG specific assays. Antibody reactivity for individuals with symptom duration less than verses greater than 28&#x02009;days is shown in D</p></caption><graphic id="nlm-graphic-5" xlink:href="TRF-9999-na-g003"/></fig></sec></sec><sec id="trf16015-sec-0015"><label>4</label><title>DISCUSSION</title><p>Persistent infection with COVID&#x02010;19 might be defined as active viral replication beyond the currently accepted post&#x02010;exposure quarantine period of 14&#x02009;days. It is unclear whether persistent PCR positivity by NP swab is due to persistent infection with transmissible virus or non&#x02010;transmissible nucleic acid fragments. These two models may not be mutually exclusive across the population and future studies are needed to determine whether individuals persistently positive by NP swab PCR represent an infectious risk. One possible study could attempt to culture live virus from individuals with persistently positive NP swabs, however care must be taken interpreting negative culture results, since viral culture is known to have limited sensitivity.<xref rid="trf16015-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> Therefore, aggressive contact tracing for individuals with persistent PCR positivity might also be considered. It is possible that persistent low&#x02010;level PCR positivity (at times below the detection limit our assays) may account for reports of COVID&#x02010;19 recurrence.<xref rid="trf16015-bib-0012" ref-type="ref">
<sup>12</sup>
</xref>, <xref rid="trf16015-bib-0013" ref-type="ref">
<sup>13</sup>
</xref>
</p><p>With the current lack of data as to whether persistent NP swab PCR positivity correlates with persistent infectivity, there are two major safety concerns relative to convalescent plasma in particular. First, even if CP donors with persistent positivity are minimally infectious, the inability to maintain social distancing and the common desire to remove a face mask during donation makes the possibility of donor room transmission high. Second, SARS&#x02010;CoV&#x02010;2 is known to infect endothelial cells and a recent report of intra&#x02010;utero transmission has emerged.<xref rid="trf16015-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> Therefore, the possibility of transfusion transmitted SARS&#x02010;CoV&#x02010;2 cannot be completely disregarded and donors with persistently positive NP swabs may have a higher chance of transmitting virus in their plasma. Realistically, transfusion transmission of SARS&#x02010;CoV&#x02010;2 may be of greater concerned if the plasma is used as a prophylaxis and provided to individuals who are not actually infected and therefore more vulnerable to transfusion transmitted disease. Perhaps pathogen inactivation should be considered when CP is used prophylactically.</p><p>Currently, healthcare organizations and other businesses are formulating plans to bring individuals back on&#x02010;site, despite the lingering threat of COVID&#x02010;19. Various strategies have been proposed to safely do this, some involving widespread testing of asymptomatic individuals. The data presented here as well as recent reports argue that the interpretation of widespread testing may be complicated by persistent PCR positivity, especially in individuals who were clinically asymptomatic and never diagnosed originally.<xref rid="trf16015-bib-0015" ref-type="ref">
<sup>15</sup>
</xref> It also raises the possibility that individuals who appear to be re&#x02010;infected were actually just persistently positive.<xref rid="trf16015-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> Ultimately, the issue becomes a practical one. For example, if a negative NP swab PCR is needed for clearance for surgery, how long should a patient be made to wait if they have persistently positive NP swabs?</p><p>One potential weakness of study is the small number of donors tested. Larger and focused studies are needed to determine if loss of taste/smell is truly correlated with the persistence of NP swab positivity, although the data presented here argues against a robust correlation. Theoretically, both could be the result of higher viral load within the nasal mucosa. The trend for donors with diarrhea to have negative NP swab results similarly may reach statistical significance with additional data. If verified, these trends might suggest different manifestations of COVID&#x02010;19 infection: gastrointestinal verses nasopharyngeal. Another potential weakness of this study is that the sensitivity of the rapid PCR assay used may have underestimated the prevalence of positive individuals.<xref rid="trf16015-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> Finally, the cutoff indices used to assess antibody strength may not be linearly related to antibody reactivity; however, it is assumed that cutoff index is positively correlated with reactivity.</p><p>Importantly, multivariate analysis of clinical history, NP swab positivity, and serology results suggests that donors who were hospitalized (suggesting more severe COVID&#x02010;19 disease) may provide more potent convalescent plasma, based on anti&#x02010;spike antibody reactivity as a measure of antiviral potency.<xref rid="trf16015-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> However, this study is limited in the number of individuals enrolled and the enrichment for individuals who had mild to moderate COVID&#x02010;19, which is to be expected in a CP donor population during the early weeks of the epidemic. Further studies are needed to ensure that these findings hold true in larger cohorts and for longer follow&#x02010;up intervals.</p></sec><sec sec-type="COI-statement" id="trf16015-sec-0016"><title>CONFLICT OF INTEREST</title><p>The authors declare no conflicts of interest.</p></sec><sec id="trf16015-sec-0017"><title>DISCLAIMERS</title><p>None.</p></sec></body><back><ref-list id="trf16015-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="trf16015-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="trf16015-cit-0001">
<string-name>
<surname>Bloch</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Shoham</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Casadevall</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Deployment of convalescent plasma for the prevention and treatment of COVID&#x02010;19</article-title>. <source xml:lang="en">J Clin Invest.</source>
<year>2020</year>;<volume>130</volume>:<fpage>2757</fpage>&#x02013;<lpage>2765</lpage>.<pub-id pub-id-type="pmid">32254064</pub-id></mixed-citation></ref><ref id="trf16015-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="trf16015-cit-0002">
<string-name>
<surname>Casadevall</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pirofski</surname>
<given-names>LA</given-names>
</string-name>. <article-title>The convalescent sera option for containing COVID&#x02010;19</article-title>. <source xml:lang="en">J Clin Invest.</source>
<year>2020</year>;<volume>130</volume>:<fpage>1545</fpage>&#x02013;<lpage>1548</lpage>.<pub-id pub-id-type="pmid">32167489</pub-id></mixed-citation></ref><ref id="trf16015-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="trf16015-cit-0003">
<string-name>
<surname>Shen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Treatment of 5 critically ill patients with COVID&#x02010;19 with convalescent plasma</article-title>. <source xml:lang="en">JAMA.</source>
<year>2020</year>;<volume>323</volume>:<fpage>1582</fpage>.</mixed-citation></ref><ref id="trf16015-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="trf16015-cit-0004">
<string-name>
<surname>Marano</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Vaglio</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pupella</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Convalescent plasma: new evidence for an old therapeutic tool?</article-title>
<source xml:lang="en">Blood Transfus.</source>
<year>2016</year>;<volume>14</volume>:<fpage>152</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">26674811</pub-id></mixed-citation></ref><ref id="trf16015-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="trf16015-cit-0005">
<collab collab-type="authors">Centers for Disease Control (CDC)</collab>
. Recommendations for Investigational COVID&#x02010;19 Convalescent Plasma. Version updated May 1, <year>2020</year>
<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma">https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma</ext-link>. Accessed May 14, 2020.</mixed-citation></ref><ref id="trf16015-bib-0006"><label>6</label><mixed-citation publication-type="miscellaneous" id="trf16015-cit-0006">
<collab collab-type="authors">Centers for Disease Control (CDC)</collab>
. Criteria for return to work for healthcare personnel with suspected or confirmed COVID&#x02010;19 (Interim Guidance). <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/return-to-work.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/return-to-work.html</ext-link>. Accessed May 14, 2020.</mixed-citation></ref><ref id="trf16015-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="trf16015-cit-0007">
<string-name>
<surname>Inagaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Crumpton</surname>
<given-names>JC</given-names>
</string-name>, et al. <article-title>Correlation between the interval of influenza virus infectivity and reuslts of diagnostic assays in a ferret model</article-title>. <source xml:lang="en">J Infect Dis.</source>
<year>2016</year>;<volume>213</volume>:<fpage>407</fpage>&#x02013;<lpage>410</lpage>.<pub-id pub-id-type="pmid">26068783</pub-id></mixed-citation></ref><ref id="trf16015-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="trf16015-cit-0008">
<string-name>
<surname>Vogel</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>van der Lubben</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>te Lintelo</surname>
<given-names>EG</given-names>
</string-name>, et al. <article-title>Pathogenic characteristics of persistent feline enteric coronavirus infection in cats</article-title>. <source xml:lang="en">Vet Res.</source>
<year>2010</year> Sep&#x02010;Oct;<volume>41</volume>:<fpage>71</fpage>.<pub-id pub-id-type="pmid">20663472</pub-id></mixed-citation></ref><ref id="trf16015-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="trf16015-cit-0009">
<string-name>
<surname>Birger</surname>
<given-names>R</given-names>
</string-name> et al. <article-title>Asymptomatic shedding of respiratory virus among ambulatory population across seasons</article-title>. <source xml:lang="en">mSphere.</source>
<year>2018</year>;<volume>3</volume>:<fpage>e00249</fpage>&#x02013;<lpage>e00218</lpage>.<pub-id pub-id-type="pmid">29997120</pub-id></mixed-citation></ref><ref id="trf16015-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="trf16015-cit-0010">
<string-name>
<surname>Bai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Presumed asymptomatic carrier transmission of COVID&#x02010;19</article-title>. <source xml:lang="en">JAMA.</source>
<year>2020</year>;<volume>323</volume>:<fpage>1406</fpage>.</mixed-citation></ref><ref id="trf16015-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="trf16015-cit-0011">
<string-name>
<surname>Armstrong</surname>
<given-names>RA</given-names>
</string-name>. <article-title>When to use the Bonferroni correction</article-title>. <source xml:lang="en">Ophthalmic Physiol Opt.</source>
<year>2014</year>;<volume>34</volume>:<fpage>502</fpage>&#x02013;<lpage>508</lpage>.<pub-id pub-id-type="pmid">24697967</pub-id></mixed-citation></ref><ref id="trf16015-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="trf16015-cit-0012">
<string-name>
<surname>van Elden</surname>
<given-names>LJ</given-names>
</string-name> et al. <article-title>Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2020</year>;<volume>34</volume>:<fpage>177</fpage>&#x02013;<lpage>183</lpage>.</mixed-citation></ref><ref id="trf16015-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="trf16015-cit-0013">
<string-name>
<surname>Chen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lei</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Recurrence of positive SARS&#x02010;CoV&#x02010;2 RNA in COVID&#x02010;19: a case report</article-title>. <source xml:lang="en">Int J Infect Dis.</source>
<year>2020</year>;<volume>93</volume>:<fpage>297</fpage>&#x02013;<lpage>299</lpage>.<pub-id pub-id-type="pmid">32147538</pub-id></mixed-citation></ref><ref id="trf16015-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="trf16015-cit-0014">
<string-name>
<surname>Sisman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jaleel</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Intrauterine transmission of Sars&#x02010;Cov&#x02010;2 infection in a preterm infant</article-title>. <source xml:lang="en">Pediatr Infect Dis J.</source> July 10, <year>2020</year>. Volume Online First.</mixed-citation></ref><ref id="trf16015-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="trf16015-cit-0015">
<string-name>
<surname>Uechi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takeshita</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Persistence of positive severe acute respiratory syndrome coronavirus&#x02010;2 reverse transcription&#x02010;polymerase chain reaction test result for 24&#x02009;days in a hospitalized asymptomatic carrier</article-title>. <source xml:lang="en">Acute Med Surg.</source>
<year>2020</year> Jan&#x02010;Dec;<volume>7</volume>:<elocation-id>e525</elocation-id>.<pub-id pub-id-type="pmid">32528710</pub-id></mixed-citation></ref><ref id="trf16015-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="trf16015-cit-0016">
<string-name>
<surname>Peng</surname>
<given-names>J</given-names>
</string-name> et al. <article-title>Seven discharged patients turning positive again for SARS&#x02010;CoV&#x02010;2 on quantitative RT&#x02010;PCR</article-title>. <source xml:lang="en">Am J Infect Control</source>. <year>2020</year>;<volume>48</volume>(<issue>6</issue>):<fpage>725</fpage>&#x02013;<lpage>726</lpage>.<pub-id pub-id-type="pmid">32317126</pub-id></mixed-citation></ref><ref id="trf16015-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="trf16015-cit-0017">
<string-name>
<surname>Mitchell</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>St. George</surname>
<given-names>K</given-names>
</string-name>. <article-title>Evaluation of the COVID19 ID NOW EUA assay</article-title>. <source xml:lang="en">J Clin Virol.</source>
<year>2020</year>;<volume>128</volume>:<elocation-id>104429</elocation-id>.<pub-id pub-id-type="pmid">32425657</pub-id></mixed-citation></ref><ref id="trf16015-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="trf16015-cit-0018">
<string-name>
<surname>Salazar</surname>
<given-names>E</given-names>
</string-name> et al. <article-title>Relationship between anti&#x02010;spike protein antibody titers and SARS&#x02010;CoV&#x02010;2 in vitro virus neutralization in convalescent plasma</article-title>. Version 1. <source xml:lang="en">bioRxiv</source>. Preprint. <year>2020</year>. PMID 32577662.</mixed-citation></ref></ref-list></back></article>